Our study highlighted a non-cytotoxic anticancer drug target for thalidomide, the IRES of bFGF, and provide the mechanistic rationale for developing IMiDs as anti-MM therapeutics. This evidence concerns the gene FGF2 and Miyoshi myopathy.